WO2000047200A1 - Combinations of formoterol and a tiotropium salt - Google Patents
Combinations of formoterol and a tiotropium salt Download PDFInfo
- Publication number
- WO2000047200A1 WO2000047200A1 PCT/EP2000/000958 EP0000958W WO0047200A1 WO 2000047200 A1 WO2000047200 A1 WO 2000047200A1 EP 0000958 W EP0000958 W EP 0000958W WO 0047200 A1 WO0047200 A1 WO 0047200A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- medicament according
- medicament
- dry powder
- pharmaceutically acceptable
- dispersion
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
- A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/04—Drugs for disorders of the respiratory system for throat disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/007—Pulmonary tract; Aromatherapy
- A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
- A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/007—Pulmonary tract; Aromatherapy
- A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
- A61K9/008—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy comprising drug dissolved or suspended in liquid propellant for inhalation via a pressurized metered dose inhaler [MDI]
Definitions
- This invention relates to combinations of formoterol and a tiotropium salt and their use for the treatment of inflammatory or obstructive airways diseases.
- Formoterol N-[2-hydroxy-5-(l-hydroxy-2-((2-(4-methoxyphenyl)-l-methylethyl)amino)- ethyl)phenyl]formamide, particularly in the form of its fumarate salt, is a bronchodilator used in the treatment of inflammatory or obstructive airways diseases.
- tiotropium bromide (l ⁇ ,2 ⁇ ,5 ⁇ ,7 ⁇ )-7-((hydroxydi-2-thienylacetyl)oxy)-9,9-dimethyl-3-oxa-9-azonia- tricyclo(3.3.1.0 2 ' 4 )-nonane bromide, in the treatment of chronic obstructive bronchitis is described in US5610163. It has now surprisingly been found that a significant unexpected therapeutic benefit, particularly a synergistic therapeutic benefit, in the treatment of inflammatory or obstructive airways diseases can be obtained by combination therapy using formoterol, or a salt or solvate thereof, and a tiotropium salt. For instance, it is possible using this combination therapy to reduce the dosages required for a given therapeutic effect considerably compared with those required using treatment with formoterol or a tiotropium salt alone, thereby minimising possibly undesirable side effects.
- this combination therapy exhibits both a fast onset of action and a long duration of action, so that patients feel a rapid improvement in their condition and, in view of the long duration of action, a reduced need for short-acting rescue medicaments, such as salbutamol or terbutaline.
- this effect is exhibited even when the two drugs are administered at the same time, i.e. in a composition containing both drugs or sequentially, so that medicaments of the invention facilitate the treatment of inflammatory or obstructive airways diseases with a medicament which need be administered only once a day.
- medicaments of the invention can be used on demand in rescue treatment of obstructive or inflammatory airways diseases, so that they facilitate treatment of such diseases with a single medicament.
- the present invention provides a medicament containing, separately or together, (A) formoterol or a pharmaceutically acceptable salt thereof or a solvate of formoterol or said salt and (B) a tiotropium salt of a pharmaceutically acceptable acid, for simultaneous, sequential or separate administration in the treatment of an inflammatory or obstructive airways disease.
- the present invention provides a method of treating an inflammatory or obstructive airways disease which comprises administering to a subject in need of such treatment effective amounts of (A) as hereinbefore defined and (B) as hereinbefore defined.
- the present invention provides a phamaceutical composition
- a phamaceutical composition comprising a mixture of effective amounts of (A) as hereinbefore defined and (B) as hereinbefore defined, optionally together with a pharmaceutically acceptable carrier.
- the present invention also provides (A) and (B) as hereinbefore defined for use in combination therapy by simultaneous, sequential or separate administration in the treatment of an inflammatory or obstructive airways disease.
- the invention further provides the use of (A) as hereinbefore defined or (B) as hereinbefore defined in the preparation of a medicament for combination therapy by simultaneous, sequential or separate administration of (A) and (B) in the treatment of an inflammatory or obstructive airways disease.
- the present invention still further provides the use of (A) and (B) as hereinbefore defined for the preparation of a medicament for combination therapy by simultaneous, sequential or separate administration in the treatment of an inflammatory or obstructive airways disease.
- salts of formoterol include, for example, salts of inorganic acids such as hydrochloric, hydrobromic, sulfuric and phosphoric acids, and organic acids such as fumaric, maleic, acetic, lactic, citric, tartaric, ascorbic, succinic, glutaric, gluconic, tricarballylic, oleic, benzoic, p-methoxybenzoic, salicylic, o- and p-hydroxybenzoic, p-chlorobenzoic, methanesulfonic, p-toluenesulfonic and 3-hydroxy-2-naphthalene carboxylic acids.
- inorganic acids such as hydrochloric, hydrobromic, sulfuric and phosphoric acids
- organic acids such as fumaric, maleic, acetic, lactic, citric, tartaric, ascorbic, succinic, glutaric, gluconic, tricarballylic, oleic, benzoic, p-me
- Component (A) may be in any isomeric form or mixture of isomeric forms, for example a pure enantiomer, a mixture of enantiomers, a racemate or a mixture thereof. It may be in the form of a solvate, for example a hydrate, thereof, for example as described in US3994974 or US5684199, and may be present in a particular crystalline form, for example as described in WO95/05805.
- component (A) is formoterol fumarate, especially in the form of the dihydrate.
- the tiotropium salt (B) is preferably tiotropium methanesulfonate or , especially, tiotropium bromide,(lcx,2 ⁇ ,4 ⁇ ,5 ⁇ ,7 ⁇ )-7-((hydroxydi-2-thienylacetyl)oxy)-9,9-dimethyl-3- oxa-9-azoniatricyclo(3.3.1.0 2 ' 4 )-nonane bromide, the preparation of which is described in US5610163.
- Administration of the medicament or pharmaceutical composition as hereinbefore described, i.e. with (A) and (B) in admixture or separate, is preferably by inhalation, i.e. (A) and (B) or the mixture thereof are in inhalable form.
- the inhalable form of the medicament i.e. of (A) and/or (B) may be, for example, an atomizable composition such as an aerosol comprising the active ingredient, i.e. (A) and (B) separately or in admixture, in solution or dispersion in a propellant, or a nebulizable composition comprising a dispersion of the active ingredient in an aqueous, organic or aqueous/organic medium.
- the inhalable form of the medicament may be an aerosol comprising a mixture of (A) and (B) in solution or dispersion in a propellant, or a combination of an aerosol containing (A) in solution or dispersion in a propellant with an aerosol containing (B) in solution or dispersion in a propellant.
- the inhalable form is a nebulizable composition comprising a dispersion of (A) and (B) in an aqueous, organic or aqueous/organic medium, or a combination of a dispersion of (A) in such a medium with a dispersion of (B) in such a medium.
- An aerosol composition suitable for use as the inhalable form of the medicament may comprise the active ingredient in solution or dispersion in a propellant, which may be chosen from any of the propellants known in the art.
- propellants include hydrocarbons such as n-propane, n-butane or isobutane or mixtures of two or more such hydrocarbons, and halogen-substituted hydrocarbons, for example fluorine-substituted methanes, ethanes, propanes, butanes, cyclopropanes or cyclobutanes, particularly 1,1,1,2-tetrafluoroethane (HFA134a) and 1,1, 1,2,3,3, 3-heptafluoropropane (HFA227), or mixtures of two or more such halogen-substituted hydrocarbons.
- hydrocarbons such as n-propane, n-butane or isobutane or mixtures of two or more such hydrocarbons
- the aerosol composition may also contain a lubricant and a surfactant, which may be chosen from those lubricants and surfactants known in the art.
- a lubricant and a surfactant which may be chosen from those lubricants and surfactants known in the art.
- Other suitable aerosol compositions include surfactant-free or substantially surfactant-free aerosol compositions.
- the aerosol composition may contain up to about 5% by weight, for example 0.002 to 5%, 0.01 to 3%, 0.015 to 2%, 0.1 to 2%, 0.5 to 2% or 0.5 to 1%, by weight of the active ingredient, based on the weight of the propellant.
- the lubricant and surfactant may be in an amount up to 5% and 0.5% respectively by weight of the aerosol composition.
- the aerosol composition may also contain a co-solvent such as ethanol in an amount up to 30% by weight of the composition, particularly for administration from a pressurised metered dose inhalation device.
- the inhalable form is a dry powder, i.e. (A) and/or (B) are present in a dry powder comprising finely divided (A) and/or (B) optionally together with a finely divided pharmaceutically acceptable carrier, which is preferably present and may be chosen from materials known as carriers in dry powder inhalation compositions, for example saccharides, including monosaccharides, disaccharides, polysaccharides and sugar alcohols such as arabinose, glucose, fructose, ribose, mannose, sucrose, trehalose, lactose, maltose, starches, dextran or mannitol.
- a finely divided pharmaceutically acceptable carrier which is preferably present and may be chosen from materials known as carriers in dry powder inhalation compositions, for example saccharides, including monosaccharides, disaccharides, polysaccharides and sugar alcohols such as arabinose, glucose, fructose, ribose, mannose, sucrose, trehalose,
- the dry powder may be in capsules of gelatin or plastic, or in blisters, for use in a dry powder inhalation device, preferably in dosage units of 1 ⁇ g to 140 ⁇ g of the active ingredient.
- the dry powder may be contained as a reservoir in a multi- dose dry powder inhalation device.
- the active ingredient may have an average particle diameter of up to about 10 ⁇ m, for example 0.1 to 5 ⁇ m, preferably 1 to 5 ⁇ m.
- the finely divided carrier where present, generally has a maximum particle diameter up to 300 ⁇ m, preferably up to 212 ⁇ m and conveniently has a mean particle diameter of 40 to lOO ⁇ m, preferably 50 to 75 ⁇ m.
- the particle size of the active ingredient, and that of the carrier where present in dry powder compositions can be reduced to the desired level by conventional methods, for example by grinding in an air-jet mill, ball mill or vibrator mill, microprecipitation, spray-drying, lyophilisation or recrystallisation from supercritical media.
- the inhalable medicament may be administered using an inhalation device suitable for the inhalable form, such devices being well known in the art.
- the invention also provides a pharmaceutical product comprising a medicament or pharmaceutical composition as hereinbefore described in inhalable form as hereinbefore described in association with one or more inhalation devices.
- the invention provides an inhalation device, or a pack of two or more inhalation devices, containing a medicament or pharmaceutical composition as hereinbefore described in inhalable form as hereinbefore described.
- the inhalation device may be an aerosol vial provided with a valve adapted to deliver a metered dose, such as 10 to 100 ⁇ l, e.g.
- an aerosol composition may be administered from a coated can, for example as described in EP-A-0642992.
- the inhalation device may be a known nebulizer, for example a conventional pneumatic nebulizer such as an airjet nebulizer, or an ultrasonic nebulizer, which may contain, for example, from 1 to 50 ml, commonly 1 to 10 ml, of the dispersion; or a hand-held nebulizer, for example an electronically controlled device such as an AERx (ex Aradigm, US) or a mechanical device such as a RESPIMAT (Boehringer Ingelheim) nebulizer which allows much smaller nebulized volumes, e.g.
- a conventional pneumatic nebulizer such as an airjet nebulizer, or an ultrasonic nebulizer, which may contain, for example, from 1 to 50 ml, commonly 1 to 10 ml, of the dispersion
- a hand-held nebulizer for example an electronically controlled device such as an AERx (ex Aradigm, US) or a mechanical
- the inhalation device may be, for example, a dry powder inhalation device adapted to deliver dry powder from a capsule or blister containing dry powder comprising a dosage unit of (A) and/or (B), or a multidose dry powder inhalation (MDPI) device adapted to deliver, for example, 5-25 mg of dry powder comprising a dosage unit of (A) and/or (B) per actuation.
- a dry powder inhalation device adapted to deliver dry powder from a capsule or blister containing dry powder comprising a dosage unit of (A) and/or (B), or a multidose dry powder inhalation (MDPI) device adapted to deliver, for example, 5-25 mg of dry powder comprising a dosage unit of (A) and/or (B) per actuation.
- MDPI multidose dry powder inhalation
- the medicament of the invention is preferably a pharmaceutical composition comprising a mixture of (A) as hereinbefore defined and (B) as hereinbefore defined, preferably together with a pharmaceutically acceptable carrier as hereinbefore described.
- the weight ratio of formoterol, or salt or solvate thereof, to tiotropium salt may be, in general, from 72:1 to 1:160, for example from 72:1 to 1:120, from 72:1 to 1:80, from 60:1 to 1:80, from 60:1 to 1:70, from 50:1 to 1:60, from 60:1 to 1:50, from 50:1 to 1:50, from 60:1 to 1:40, from 50:1 to 1:40, from 50:1 to 1:30, from 50:1 to 1:20, from 50:1 to 1:30, from 50:1 to 1:20, from 50:1 to 1:10, from 40:1 to 1:20, from 40:1 to 1:10, from 30:1 to 1:20, from 30:1 to 1:10, from 20:1 to 1:20, from 20:1 to 1:10, from 20:1 to 1:5, from 16:1 to 1:4, from 10:1 to 1:5, from 6:1 to 1:4, or from 4:1 to 1:3.
- this ratio is from 3:1 to 1:3, for example from 2.5:1 to 1:2, from 2:1 to 1:2, from 1.5:1 to 1:1.5, or from 1.5:1 to 1:1.2.
- the two drugs may be administered separately in the same ratio.
- Specific examples of this ratio include 3:1, 2.9:1, 2.8:1, 2.7:1. 2.6:1. 2.5:1. 2.4:1, 2.3:1, 2.2:1, 2.1:1, 2:1,1.9:1, 1.8:1, 1.7:1, 1.6:1, 1.5:1, 1.4:1, 1.3:1, 1.2:1, 1.1:1, 1:1, 1:1.1, 1:1.2, 1:1.3, 1:1.4, 1:1.5, 1:1.6, 1:1.7, 1:1.8, 1:1.9 and 1:2.
- a suitable daily dose of formoterol, or salt or solvate thereof, particularly as formoterol fumarate dihydrate, for inhalation may be from 1 to 72 ⁇ g, for example from 1 to 60 ⁇ g, generally from 3 to 50 ⁇ g, preferably from 6 to 48 ⁇ g, for instance from 6 to 24 ⁇ g.
- a suitable daily dose of tiotropium salt, particularly as tiotropium bromide, for inhalation may be from 1 to 160 ⁇ g, for example from 1 to 120 ⁇ g, from 1 to 80 ⁇ g, from 1 to 70 ⁇ g, from 1 to 60 ⁇ g, from 1 to 50 ⁇ g, from 1 to 40 ⁇ g, from 1 to 25 ⁇ g, preferably from 3 to 36 ⁇ g, for instance from 9 to 36 ⁇ g.
- the precise dose used will of course depend on the condition to be treated, the patient and the efficiency of the inhalation device.
- the unit doses of (A) and (B) and their frequency of administration may be chosen accordingly.
- a suitable unit dose of formoterol component (A), particularly as formoterol fumarate dihydrate, may be from 1 to 72 ⁇ g, for example from 1 to 60 ⁇ g, generally from 3 to 48 ⁇ g, preferably from 6 to 36 ⁇ g, especially from 12 to 24 ⁇ g.
- a suitable unit dose of tiotropium salt (B), particularly as tiotropium bromide, may be from 1 ⁇ g to 80 ⁇ g, for example from 1 ⁇ g to 50 ⁇ g, preferably from 3 ⁇ g to 36 ⁇ g, especially from 9 to 36 ⁇ g.
- These unit doses may suitably be administered once or twice daily in accordance with the suitable daily dose mentioned hereinbefore. For on demand usage, unit doses of 6 ⁇ g to 12 ⁇ g of (A) and 3 ⁇ g to 36 ⁇ g of (B) are preferred.
- the capsules may suitably contain, where (A) is formoterol fumarate dihydrate, and (B) is tiotropium bromide, from 3 ⁇ g to 36 ⁇ g of (A), preferably from 6 ⁇ g to 24 ⁇ g of (A), especially from 12 ⁇ g to 24 ⁇ g of (A), and from 3 ⁇ g to 80 ⁇ g of (B), preferably from 5 ⁇ g to 50 ⁇ g of (B), especially from 9 to 36 ⁇ g of (B), together with a pharmaceutically acceptable carrier as hereinbefore described in an amount to bring the total weight of dry powder per capsule to between 5 mg and 50mg, for example 5mg, lOmg, 15mg, 20mg, 25mg, 30mg, 35mg, 40mg, 45
- the medicament of the invention is a pharmaceutical composition which is a dry powder for administration from a reservoir of a multi-dose dry powder inhaler adapted to deliver 3mg to 25mg of powder containing a unit dose of (A) and (B) per actuation, for example, where (A) is formoterol fumarate dihydrate, and (B) is tiotropium bromide, a powder comprising, by weight, 3 to 36 parts, preferably 6 to 24 parts, especially 12 to 24 parts of (A); 3 to 80 parts, preferably 5 to 50 parts, especially 9 to 36 parts of (B); and 2884 to 24994 parts, preferably 4884 to 14994 parts, especially 4884 to 9994 parts of a pharmaceutically acceptable carrier as hereinbefore described.
- the invention also provides a pharmaceutical kit comprising (A) and (B) as hereinbefore defined in separate unit dosage forms, said forms being suitable for administration of (A) and (B) in effective amounts.
- a kit suitably further comprises one or more inhalation devices for administration of (A) and (B).
- the kit may comprise one or more dry powder inhalation devices adapted to deliver dry powder from a capsule, together with capsules containing a dry powder comprising a dosage unit of (A) and capsules containing a dry powder comprising a dosage unit of (B).
- the kit may comprise a multidose dry powder inhalation device containing in the reservoir thereof a dry powder comprising (A) and a multidose dry powder inhalaiton device containing in the reservoir thereof a dry powder comprising (B).
- the kit may comprise a metered dose inhaler containing an aerosol comprising comprising (A) in a propellant and a metered dose inhaler containing an aerosol comprising (B) in a propellant.
- Treatment of inflammatory or obstructive airways diseases in accordance with the invention may be symptomatic or prophylactic treatment.
- Inflammatory or obstructive airways diseases to which the present invention is applicable include asthma of whatever type or genesis including both intrinsic (non-allergic) asthma and extrinsic (allergic) asthma.
- Treatment of asthma is also to be understood as embracing treatment of subjects, e.g. of less than 4 or 5 years of age, exhibiting wheezing symptoms and diagnosed or diagnosable as "whez infants", an established patient category of major medical concern and now often identified as incipient or early-phase asthmatics.
- Prophylactic efficacy in the treatment of asthma will be evidenced by reduced frequency or severity of symptomatic attack, e.g. of acute asthmatic or bronchoconstrictor attack, improvement in lung function or improved airways hyperreactivity. It may further be evidenced by reduced requirement for other, symptomatic therapy, i.e. therapy for or intended to restrict or abort symptomatic attack when it occurs, for example anti- inflammatory (e.g. corticosteroid) or bronchodilatory. Prophylactic benefit in asthma may in particular be apparent in subjects prone to "morning dipping".
- “Morning dipping” is a recognised asthmatic syndrome, common to a substantial percentage of asthmatics and characterised by asthma attack, e.g. between the hours of about 4 to 6 am, i.e. at a time normally substantially distant form any previously administered symptomatic asthma therapy.
- inflammatory or obstructive airways diseases and conditions to which the present invention is applicable include acute lung injury (All), acute respiratory distress syndrome (ARDS), chronic obstructive pulmonary, airways or lung disease (COPD, COAD or COLD), including chronic bronchitis and emphysema, bronchiectasis and exacerbation of airways hyperreactivity consequent to other drug therapy, in particular other inhaled drug therapy.
- pneumoconiosis an inflammatory, commonly occupational, disease of the lungs, frequently accompanied by airways obstruction, whether chronic or acute, and occasioned by repeated inhalation of dusts
- pneumoconiosis an inflammatory, commonly occupational, disease of the lungs, frequently accompanied by airways obstruction, whether chronic or acute, and occasioned by repeated inhalation of dusts
- aluminosis an inflammatory, commonly occupational, disease of the lungs, frequently accompanied by airways obstruction, whether chronic or acute, and occasioned by repeated inhalation of dusts
- aluminosis anthracosis
- asbestosis chalicosis
- ptilosis ptilosis
- siderosis silicosis
- tabacosis tabacosis and byssinosis.
- Example 1 Aerosol Composition for Metered Dose Inhaler
- a dry powder suitable for delivery from the reservoir of the multi-dose inhaler described in WO97/20589 is prepared by mixing 12 parts of formoterol fumarate dihydrate which has been ground to a mean particle diameter of l-5 ⁇ m in an air-jet mill, 18 parts of tiotropium bromide which has been similarly ground to a mean particle diameter of l-5 ⁇ m and 4970 parts of lactose monohydrate having a particle diameter below 212 ⁇ m.
- Example 3 is repeated, but using the amounts of the ingredients shown in the table below in place of the amounts used in that Example :
- Gelatin capsules suitable for use in a capsule inhaler such as that described in US3991761 are prepared, each capsule containing a dry powder obtained by mixing 12 ⁇ g of formoterol fumarate dihydrate which has been ground to a mean particle diameter of 1 to 5 ⁇ m in an air jet mill, 18 ⁇ g of tiotropium bromide which has been similarly ground to a mean particle diameter of 1 to 5 ⁇ m and 24970 ⁇ g of lactose monohydrate having a particle diameter below 212 ⁇ m.
- Example 93 is repeated, but using the amounts of the ingredients shown in the table below in place of the amounts used in that Example :
- Example 3 is repeated, but using the amounts of the ingredients shown in the table below in place of the amounts used in that Example:
- Example 93 is repeated, but using the amounts of the ingredients shown in the table below in place of the amounts used in that Example:
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pulmonology (AREA)
- Pain & Pain Management (AREA)
- Engineering & Computer Science (AREA)
- Otolaryngology (AREA)
- Rheumatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Silicates, Zeolites, And Molecular Sieves (AREA)
- Inorganic Compounds Of Heavy Metals (AREA)
- Transition And Organic Metals Composition Catalysts For Addition Polymerization (AREA)
- Cephalosporin Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Detergent Compositions (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Description
Claims
Priority Applications (18)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CA002360248A CA2360248C (en) | 1999-02-08 | 2000-02-07 | Combinations of formoterol and a tiotropium salt |
IL14398600A IL143986A0 (en) | 1999-02-08 | 2000-02-07 | Combinations of formoterol and a tiotropium salt |
SK1127-2001A SK285884B6 (en) | 1999-02-08 | 2000-02-07 | Combined preparation of formoterol and tiotropium salt, its use and pharmaceutical kit comprising the same |
NZ513304A NZ513304A (en) | 1999-02-08 | 2000-02-07 | Combinations of formoterol and a tiotropium salt |
SI200030922T SI1158970T1 (en) | 1999-02-08 | 2000-02-07 | Combinations of formoterol and a tiotropium salt |
DE60030844T DE60030844T2 (en) | 1999-02-08 | 2000-02-07 | COMBINATIONS OF FORMOTEROL AND TIOTROPIUM SALT |
BRPI0008039A BRPI0008039B1 (en) | 1999-02-08 | 2000-02-07 | medicament, use of formoterol combinations and a tiotropium salt for preparation thereof, as well as a pharmaceutical kit. |
AU24419/00A AU770632B2 (en) | 1999-02-08 | 2000-02-07 | Combinations of formoterol and a tiotropium salt |
JP2000598152A JP2002536408A (en) | 1999-02-08 | 2000-02-07 | Combination of formoterol and tiotropium salt |
KR1020017009941A KR20010101806A (en) | 1999-02-08 | 2000-02-07 | Combinations of Formoterol and a Tiotropium Salt |
EP00902663A EP1158970B1 (en) | 1999-02-08 | 2000-02-07 | Combinations of formoterol and a tiotropium salt |
PL350583A PL206965B1 (en) | 1999-02-08 | 2000-02-07 | Combinations of formoterol and a tiotropium salt |
IL143986A IL143986A (en) | 1999-02-08 | 2001-06-25 | Combinations of formoterol and a tiotropium salt |
NO20013460A NO329911B1 (en) | 1999-02-08 | 2001-07-12 | Medicament containing formoterol and a tiotropium salt, use thereof and a pharmaceutical device containing said drug |
US09/924,246 US6537524B1 (en) | 1999-02-08 | 2001-08-08 | Combinations of formoterol and a tiotropium salt |
US10/365,310 US20030125350A1 (en) | 1999-02-08 | 2003-02-12 | Combination of formoterol and a tiotropium salt |
US11/288,548 US20060083692A1 (en) | 1999-02-08 | 2005-11-29 | Combination of formoterol and a tiotropium salt |
CY20061101480T CY1105707T1 (en) | 1999-02-08 | 2006-10-16 | COMBINATIONS OF FORMOTEROL AND A TRIOTROP SALT |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GBGB9902689.0A GB9902689D0 (en) | 1999-02-08 | 1999-02-08 | Organic compounds |
GB9902689.0 | 1999-02-08 |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US09/924,246 Continuation US6537524B1 (en) | 1999-02-08 | 2001-08-08 | Combinations of formoterol and a tiotropium salt |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2000047200A1 true WO2000047200A1 (en) | 2000-08-17 |
Family
ID=10847254
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/EP2000/000958 WO2000047200A1 (en) | 1999-02-08 | 2000-02-07 | Combinations of formoterol and a tiotropium salt |
Country Status (27)
Country | Link |
---|---|
US (3) | US6537524B1 (en) |
EP (1) | EP1158970B1 (en) |
JP (1) | JP2002536408A (en) |
KR (1) | KR20010101806A (en) |
CN (1) | CN1338928A (en) |
AT (1) | ATE339954T1 (en) |
AU (1) | AU770632B2 (en) |
BR (1) | BRPI0008039B1 (en) |
CA (1) | CA2360248C (en) |
CY (1) | CY1105707T1 (en) |
CZ (1) | CZ302198B6 (en) |
DE (1) | DE60030844T2 (en) |
DK (1) | DK1158970T3 (en) |
ES (1) | ES2270806T3 (en) |
GB (1) | GB9902689D0 (en) |
HU (1) | HUP0200083A3 (en) |
ID (1) | ID29181A (en) |
IL (2) | IL143986A0 (en) |
NO (1) | NO329911B1 (en) |
NZ (1) | NZ513304A (en) |
PL (1) | PL206965B1 (en) |
PT (1) | PT1158970E (en) |
RU (1) | RU2238085C2 (en) |
SK (1) | SK285884B6 (en) |
TR (1) | TR200102226T2 (en) |
WO (1) | WO2000047200A1 (en) |
ZA (1) | ZA200105648B (en) |
Cited By (29)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR2801506A1 (en) * | 1999-11-30 | 2001-06-01 | Novartis Ag | New use of dry powder containing formoterol for preparation of an inhalable medicament for the treatment of chronic obstructive pulmonary disease |
WO2002030389A1 (en) * | 2000-10-12 | 2002-04-18 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Novel tiotropium-containing inhalation powder |
US6433027B1 (en) | 1999-05-12 | 2002-08-13 | Boehringer Ingelheim Pharma Kg | Medicament compositions based on tiotropium bromide and formoterol fumarate |
WO2002072095A2 (en) * | 2001-03-13 | 2002-09-19 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Tiotropium salts for treating inflammatory diseases |
WO2002100319A2 (en) * | 2001-06-13 | 2002-12-19 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Method for cleaning hard gelatine capsules |
US6585959B2 (en) | 2000-10-12 | 2003-07-01 | Boehringer Ingelheim Pharma Kg | Process for preparing powder formulations |
US6667344B2 (en) | 2001-04-17 | 2003-12-23 | Dey, L.P. | Bronchodilating compositions and methods |
WO2004024156A1 (en) * | 2002-09-13 | 2004-03-25 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Tiotropium salts for reducing respiratory mortality rate |
WO2004047796A2 (en) * | 2002-11-28 | 2004-06-10 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Pulverulent formulation for inhalation containing tiotropium |
US6890517B2 (en) | 2000-10-31 | 2005-05-10 | Boehringer Ingelheim Pharma Kg | Inhalable formulation of a solution containing a tiotropium salt |
US7078412B2 (en) | 1999-07-14 | 2006-07-18 | Almirall Prodesfarma Ag | Quinuclidine derivatives and medicinal compositions containing the same |
US7214687B2 (en) | 1999-07-14 | 2007-05-08 | Almirall Ag | Quinuclidine derivatives and medicinal compositions containing the same |
EP2080523A1 (en) * | 2008-01-15 | 2009-07-22 | CHIESI FARMACEUTICI S.p.A. | Compositions comprising an antimuscarinic and a long-acting beta-agonist |
US7763280B2 (en) | 2002-11-28 | 2010-07-27 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Tiotropium containing powder formulation for inhalation |
EP2319582A1 (en) | 2002-08-29 | 2011-05-11 | Cipla Ltd. | Pharmaceutical products and compositions comprising formoterol, budesonide and tiotropium or oxitropium |
WO2011037551A3 (en) * | 2009-09-23 | 2011-06-09 | Mahmut Bilgic | Carrying of a combination containing tiotropium in a blister strip |
WO2011037549A3 (en) * | 2009-09-23 | 2011-06-09 | Bilgic Mahmut | Dry powder formulation of tiotropium carried in blister strip |
WO2011078816A1 (en) | 2009-12-25 | 2011-06-30 | Bilgic Mahmut | Dry powder combination of tiotropium, formoterol and a cromoglicic acid derivative |
US8022082B2 (en) | 2002-04-09 | 2011-09-20 | Boehringer Ingelheim Pharma Gmbh & Co., Kg | Method for the administration of an anticholinergic by inhalation |
US8044205B2 (en) | 2006-07-21 | 2011-10-25 | Laboratorios Almirall, S.A. | Process for manufacturing 3(R)-(2-hydroxy-2,2-dithien-2-ylacetoxy)-1-(3-phenoxypropyl)-1-azoniabicyclo[2.2.2]octane bromide |
WO2011049538A3 (en) * | 2009-10-20 | 2011-11-03 | Bilgic Mahmut | Pharmaceutical composition in dry powder form |
US8834931B2 (en) | 2009-12-25 | 2014-09-16 | Mahmut Bilgic | Dry powder formulation containing tiotropium for inhalation |
US9254262B2 (en) | 2008-03-13 | 2016-02-09 | Almirall, S.A. | Dosage and formulation |
EP3053921A1 (en) * | 2002-03-20 | 2016-08-10 | Boehringer Ingelheim Pharma GmbH & Co. KG | Crystalline micronisate of tiotropium bromide |
US9597396B2 (en) | 2001-04-17 | 2017-03-21 | Mylan Specialty Lp | Formoterol/steroid bronchodilating compositions and methods of use thereof |
US9737520B2 (en) | 2011-04-15 | 2017-08-22 | Almirall, S.A. | Aclidinium for use in improving the quality of sleep in respiratory patients |
NO342935B1 (en) * | 2000-05-22 | 2018-09-03 | Chiesi Farm Spa | Stable pharmaceutical solution formulations for use in metered dose inhalers |
US10085974B2 (en) | 2008-03-13 | 2018-10-02 | Almirall, S.A. | Dosage and formulation |
EP2228064B1 (en) | 2004-05-18 | 2019-12-11 | Novartis AG | Pharmaceutical composition containing glycopyrrolate and a beta2 adrenoceptor agonist |
Families Citing this family (33)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB9902689D0 (en) * | 1999-02-08 | 1999-03-31 | Novartis Ag | Organic compounds |
US20100197719A1 (en) * | 1999-05-12 | 2010-08-05 | Boehringer Ingelheim Pharma Kg | Medicament compositions containing anticholinergically-effective compounds and betamimetics |
US20040002548A1 (en) * | 1999-05-12 | 2004-01-01 | Boehringer Ingelheim Pharma Kg | Medicament compositions containing anticholinergically-effective compounds and betamimetics |
US20030026766A1 (en) * | 2000-04-13 | 2003-02-06 | Mark Sanders | Medicaments for treating respiratory disorders comprising formoterol and fluticasone |
IT1318514B1 (en) * | 2000-05-12 | 2003-08-27 | Chiesi Farma Spa | FORMULATIONS CONTAINING A GLUCOCORTICOSTEROID DRUG FOR THE TREATMENT OF BRONCOPOLMONARY DISEASES. |
US20060257324A1 (en) * | 2000-05-22 | 2006-11-16 | Chiesi Farmaceutici S.P.A. | Pharmaceutical solution formulations for pressurised metered dose inhalers |
GB0029562D0 (en) * | 2000-12-04 | 2001-01-17 | Novartis Ag | Organic compounds |
US20030070679A1 (en) * | 2001-06-01 | 2003-04-17 | Boehringer Ingelheim Pharma Kg | Capsules containing inhalable tiotropium |
US20030008001A1 (en) * | 2001-06-13 | 2003-01-09 | Boehringer Ingelheim Pharma Kg | Process for cleaning hard gelatine capsules |
US20030018019A1 (en) * | 2001-06-23 | 2003-01-23 | Boehringer Ingelheim Pharma Kg | Pharmaceutical compositions based on anticholinergics, corticosteroids and betamimetics |
US7931022B2 (en) * | 2001-10-19 | 2011-04-26 | Respirks, Inc. | Method and apparatus for dispensing inhalator medicament |
US7311894B2 (en) * | 2002-03-28 | 2007-12-25 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | HFA suspension formulations containing an anticholinergic |
US7244415B2 (en) * | 2002-03-28 | 2007-07-17 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | HFA suspension formulations of an anhydrate |
UA80123C2 (en) | 2002-04-09 | 2007-08-27 | Boehringer Ingelheim Pharma | Inhalation kit comprising inhalable powder of tiotropium |
SE527200C2 (en) * | 2003-06-19 | 2006-01-17 | Microdrug Ag | Administration of metered dry powder combined doses of finely divided dry medication powders involves selecting first and second medicaments for forming of pharmaceutical, combined doses |
US20050026948A1 (en) * | 2003-07-29 | 2005-02-03 | Boehringer Ingelheim International Gmbh | Medicaments for inhalation comprising an anticholinergic and a betamimetic |
DE102004016179A1 (en) * | 2004-03-30 | 2005-10-20 | Boehringer Ingelheim Pharma | Compounds for the treatment of proliferative processes |
ES2257152B1 (en) * | 2004-05-31 | 2007-07-01 | Laboratorios Almirall S.A. | COMBINATIONS THAT INCLUDE ANTIMUSCARINIC AGENTS AND BETA-ADRENERGIC AGONISTS. |
AU2005263577C1 (en) | 2004-07-16 | 2010-08-26 | Proteosys Ag | Muscarinic antagonists with PARP and SiR modulating activity as cytoprotective agents |
JP2008538758A (en) * | 2005-04-23 | 2008-11-06 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | Pharmaceutical composition for inhalation containing beta-receptor stimulant and steroid in addition to anticholinergic |
US20060239935A1 (en) * | 2005-04-23 | 2006-10-26 | Boehringer Ingelheim International Gmbh | Compositions for inhalation |
JP2009504604A (en) * | 2005-08-06 | 2009-02-05 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | Use of tiotropium salt in the treatment of severe persistent asthma |
AU2006334367B2 (en) * | 2006-01-04 | 2012-11-08 | Boehringer Ingelheim International Gmbh | Use of tiotropium salts in the treatment of moderate persistent asthma |
CA2608561A1 (en) * | 2007-10-29 | 2009-04-29 | Carl Paluszkiewicz | Motorcycle wind deflector accessory support |
GB2468073B (en) * | 2008-02-26 | 2012-09-05 | Elevation Pharmaceuticals Inc | Method and system for the treatment of chronic obstructive pulmonary disease with nebulized anticholinergic administrations |
US20100055045A1 (en) | 2008-02-26 | 2010-03-04 | William Gerhart | Method and system for the treatment of chronic obstructive pulmonary disease with nebulized anticholinergic administrations |
WO2010081825A2 (en) | 2009-01-13 | 2010-07-22 | Proteosys Ag | Pirenzepine as an agent in cancer treatment |
LT2435025T (en) | 2009-05-29 | 2016-09-26 | Pearl Therapeutics, Inc. | Respiratory delivery of active agents |
US8815258B2 (en) | 2009-05-29 | 2014-08-26 | Pearl Therapeutics, Inc. | Compositions, methods and systems for respiratory delivery of two or more active agents |
CN103110584A (en) * | 2013-01-29 | 2013-05-22 | 青岛大学 | Tiotropium bromide powder inhalation and preparation method thereof |
KR102391332B1 (en) | 2013-03-15 | 2022-04-26 | 펄 테라퓨틱스 인코포레이티드 | Methods and systems for conditioning of particulate crystalline materials |
CN105125542A (en) * | 2015-08-23 | 2015-12-09 | 杭州紫金医药科技有限公司 | Medicine composition with tiotropium bromide and formoterol, application of medicine composition and preparation |
EP3525773A1 (en) | 2016-10-14 | 2019-08-21 | Glenmark Specialty S.A. | Nebulizable compositions of tiotropium and formoterol |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1995005805A1 (en) * | 1993-08-27 | 1995-03-02 | Astra Aktiebolag | Process for conditioning substances |
WO2000007567A1 (en) * | 1998-08-04 | 2000-02-17 | Jago Research Ag | Medicinal aerosol formulations |
WO2000016814A1 (en) * | 1998-09-22 | 2000-03-30 | Aeropharm Technology Incorporated | Medicinal aerosol formulation |
DE19847970A1 (en) * | 1998-10-17 | 2000-04-20 | Boehringer Ingelheim Pharma | Stable concentrated liquid formulation of inhalable drug, e.g. formoterol or salbutamol, in solution or suspension medium, used after dilution for treatment of respiratory disorders by inhalation |
Family Cites Families (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US115681A (en) * | 1871-06-06 | Improvement in water-wheels | ||
US5610163A (en) * | 1989-09-16 | 1997-03-11 | Boehringer Ingelheim Gmbh | Esters of thienyl carboxylic acids and amino alcohols and their quaternization products |
US5874063A (en) * | 1991-04-11 | 1999-02-23 | Astra Aktiebolag | Pharmaceutical formulation |
DE69232462T2 (en) * | 1991-12-18 | 2002-10-10 | Astrazeneca Ab, Soedertaelje | COMPOSITION CONTAINING FORMOTEROL AND BUDESONIDE |
EP0673240B1 (en) * | 1992-12-09 | 1999-03-24 | Boehringer Ingelheim Pharmaceuticals Inc. | Stabilized medicinal aerosol solution formulations |
US5603918A (en) | 1995-06-09 | 1997-02-18 | Boehringer Ingelheim Pharmaceuticals, Inc. | Aerosol composition of a salt of ipratropium and a salt of albuterol |
WO1998034595A1 (en) * | 1997-02-05 | 1998-08-13 | Jago Research Ag | Medical aerosol formulations |
DE19835335C1 (en) * | 1998-08-05 | 1999-11-25 | Draeger Sicherheitstech Gmbh | Infra optical gas sensor for measuring carbon dioxide |
DE19835346A1 (en) * | 1998-08-05 | 2000-02-10 | Boehringer Ingelheim Pharma | Two-part capsule for pharmaceutical preparations for powder inhalers |
DE19847968A1 (en) * | 1998-10-17 | 2000-04-20 | Boehringer Ingelheim Pharma | Separate storage of an active material and a solvent comprises a closure cap and a container, with a chamber attached to the unit. |
DE19847969A1 (en) | 1998-10-17 | 2000-04-20 | Boehringer Ingelheim Pharma | Stable liquid formulation of formoterol in solution or suspension medium, used after dilution for treatment of asthma by inhalation |
US6235725B1 (en) * | 1998-10-30 | 2001-05-22 | Baker Norton Pharmaceuticals, Inc. | Methods and compositions for the prevention of tolerance to medications |
GB9902689D0 (en) * | 1999-02-08 | 1999-03-31 | Novartis Ag | Organic compounds |
DE19921693A1 (en) * | 1999-05-12 | 2000-11-16 | Boehringer Ingelheim Pharma | Pharmaceutical composition for treating respiratory disorders, e.g. asthma, comprises combination of anticholinergic and beta-mimetic agents having synergistic bronchospasmolytic activity and reduced side-effects |
US6471435B1 (en) * | 1999-11-05 | 2002-10-29 | Multibeam Systems, Inc. | Flexural joint |
-
1999
- 1999-02-08 GB GBGB9902689.0A patent/GB9902689D0/en not_active Ceased
-
2000
- 2000-02-07 IL IL14398600A patent/IL143986A0/en active IP Right Grant
- 2000-02-07 CA CA002360248A patent/CA2360248C/en not_active Expired - Fee Related
- 2000-02-07 KR KR1020017009941A patent/KR20010101806A/en not_active Application Discontinuation
- 2000-02-07 NZ NZ513304A patent/NZ513304A/en not_active IP Right Cessation
- 2000-02-07 AT AT00902663T patent/ATE339954T1/en active
- 2000-02-07 BR BRPI0008039A patent/BRPI0008039B1/en not_active IP Right Cessation
- 2000-02-07 JP JP2000598152A patent/JP2002536408A/en active Pending
- 2000-02-07 CZ CZ20012856A patent/CZ302198B6/en not_active IP Right Cessation
- 2000-02-07 AU AU24419/00A patent/AU770632B2/en not_active Ceased
- 2000-02-07 PT PT00902663T patent/PT1158970E/en unknown
- 2000-02-07 ID IDW00200101600D patent/ID29181A/en unknown
- 2000-02-07 DK DK00902663T patent/DK1158970T3/en active
- 2000-02-07 TR TR2001/02226T patent/TR200102226T2/en unknown
- 2000-02-07 CN CN00803395A patent/CN1338928A/en active Pending
- 2000-02-07 DE DE60030844T patent/DE60030844T2/en not_active Expired - Lifetime
- 2000-02-07 WO PCT/EP2000/000958 patent/WO2000047200A1/en active IP Right Grant
- 2000-02-07 RU RU2001123923A patent/RU2238085C2/en not_active IP Right Cessation
- 2000-02-07 PL PL350583A patent/PL206965B1/en unknown
- 2000-02-07 SK SK1127-2001A patent/SK285884B6/en not_active IP Right Cessation
- 2000-02-07 ES ES00902663T patent/ES2270806T3/en not_active Expired - Lifetime
- 2000-02-07 HU HU0200083A patent/HUP0200083A3/en not_active Application Discontinuation
- 2000-02-07 EP EP00902663A patent/EP1158970B1/en not_active Revoked
-
2001
- 2001-06-25 IL IL143986A patent/IL143986A/en not_active IP Right Cessation
- 2001-07-10 ZA ZA200105648A patent/ZA200105648B/en unknown
- 2001-07-12 NO NO20013460A patent/NO329911B1/en not_active IP Right Cessation
- 2001-08-08 US US09/924,246 patent/US6537524B1/en not_active Expired - Lifetime
-
2003
- 2003-02-12 US US10/365,310 patent/US20030125350A1/en not_active Abandoned
-
2005
- 2005-11-29 US US11/288,548 patent/US20060083692A1/en not_active Abandoned
-
2006
- 2006-10-16 CY CY20061101480T patent/CY1105707T1/en unknown
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1995005805A1 (en) * | 1993-08-27 | 1995-03-02 | Astra Aktiebolag | Process for conditioning substances |
WO2000007567A1 (en) * | 1998-08-04 | 2000-02-17 | Jago Research Ag | Medicinal aerosol formulations |
WO2000016814A1 (en) * | 1998-09-22 | 2000-03-30 | Aeropharm Technology Incorporated | Medicinal aerosol formulation |
DE19847970A1 (en) * | 1998-10-17 | 2000-04-20 | Boehringer Ingelheim Pharma | Stable concentrated liquid formulation of inhalable drug, e.g. formoterol or salbutamol, in solution or suspension medium, used after dilution for treatment of respiratory disorders by inhalation |
Non-Patent Citations (2)
Title |
---|
BARNES P J: "Chronic obstructive pulmonary disease: new opportunities for drug development", TRENDS IN PHARMACOLOGICAL SCIENCES,GB,ELSEVIER TRENDS JOURNAL, CAMBRIDGE, vol. 19, no. 10, October 1998 (1998-10-01), pages 415 - 423, XP004156947, ISSN: 0165-6147 * |
LECKIE M.J. ET AL: "Novel therapy for COPD.", EXPERT OPINION ON INVESTIGATIONAL DRUGS, (2000) 9/1 (3-23)., XP000911149 * |
Cited By (74)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6455524B1 (en) | 1999-03-12 | 2002-09-24 | Boehringer Ingelheim Pharma Kg | Medicament compositions based on anticholinergically-effective compounds and beta-mimetics |
EP1570861A2 (en) * | 1999-05-12 | 2005-09-07 | Boehringer Ingelheim Pharma GmbH & Co.KG | Pharmaceutical compositions based on anticholinergically effective compounds and beta-mimetics |
EP2266621A3 (en) * | 1999-05-12 | 2013-01-23 | Boehringer Ingelheim Pharma GmbH & Co. KG | Pharmaceutical compositions based on anticholinergically effective compounds and beta-mimetics |
EP2269647A3 (en) * | 1999-05-12 | 2012-04-18 | Boehringer Ingelheim Pharma GmbH & Co. KG | Pharmaceutical compositions based on anticholinergically effective compounds and beta-mimetics |
EP2269648A3 (en) * | 1999-05-12 | 2012-04-18 | Boehringer Ingelheim Pharma GmbH & Co. KG | Pharmaceutical compositions based on anticholinergically effective compounds and beta-mimetics |
US6433027B1 (en) | 1999-05-12 | 2002-08-13 | Boehringer Ingelheim Pharma Kg | Medicament compositions based on tiotropium bromide and formoterol fumarate |
EP1570861A3 (en) * | 1999-05-12 | 2010-12-29 | Boehringer Ingelheim Pharma GmbH & Co.KG | Pharmaceutical compositions based on anticholinergically effective compounds and beta-mimetics |
US7750023B2 (en) | 1999-07-14 | 2010-07-06 | Almirall, S.A. | Quinuclidine derivatives and medicinal compositions containing the same |
US7078412B2 (en) | 1999-07-14 | 2006-07-18 | Almirall Prodesfarma Ag | Quinuclidine derivatives and medicinal compositions containing the same |
US10588895B2 (en) | 1999-07-14 | 2020-03-17 | Almirall, S.A. | Quinuclidine derivatives and medicinal compositions containing the same |
US7897617B2 (en) | 1999-07-14 | 2011-03-01 | Almirall Prodesfarma S.A. | Quinuclidine derivatives and medicinal compositions containing the same |
US7214687B2 (en) | 1999-07-14 | 2007-05-08 | Almirall Ag | Quinuclidine derivatives and medicinal compositions containing the same |
US7196098B2 (en) | 1999-07-14 | 2007-03-27 | Almirall Prodesfarma Ag | Quinuclidine derivatives and medicinal compositions containing the same |
US10034867B2 (en) | 1999-07-14 | 2018-07-31 | Almirall, S.A. | Quinuclidine derivatives and medicinal compositions containing the same |
US9687478B2 (en) | 1999-07-14 | 2017-06-27 | Almirall, S.A. | Quinuclidine derivatives and medicinal compositions containing the same |
US9333195B2 (en) | 1999-07-14 | 2016-05-10 | Almirall, S.A. | Quinuclidine derivatives and medicinal compositions containing the same |
US8129405B2 (en) | 1999-07-14 | 2012-03-06 | Almirall Prodesfarma S.A. | Quinuclidine derivatives and medicinal compositions containing the same |
US9056100B2 (en) | 1999-07-14 | 2015-06-16 | Almirall, S.A. | Quinuclidine derivatives and medicinal compositions containing the same |
US6887459B1 (en) | 1999-11-30 | 2005-05-03 | Novartis, Ag | Aerosol composition comprising formoterol |
WO2001039745A3 (en) * | 1999-11-30 | 2001-12-20 | Novartis Ag | Aerosol composition comprising formoterol |
FR2801506A1 (en) * | 1999-11-30 | 2001-06-01 | Novartis Ag | New use of dry powder containing formoterol for preparation of an inhalable medicament for the treatment of chronic obstructive pulmonary disease |
WO2001039745A2 (en) * | 1999-11-30 | 2001-06-07 | Novartis Ag | Aerosol composition comprising formoterol |
JP2003515551A (en) * | 1999-11-30 | 2003-05-07 | ノバルティス アクチエンゲゼルシャフト | Aerosol containing formoterol |
EP2011484A2 (en) | 1999-11-30 | 2009-01-07 | Novartis Ag | Use of a dry powder composition of formoterol in the treatment of chronic obstructive pulmonary disease |
ES2178943A1 (en) * | 1999-11-30 | 2003-01-01 | Novartis Ag | Aerosol composition comprising formoterol |
NO342935B1 (en) * | 2000-05-22 | 2018-09-03 | Chiesi Farm Spa | Stable pharmaceutical solution formulations for use in metered dose inhalers |
USRE38912E1 (en) * | 2000-10-12 | 2005-12-06 | Boehringer Ingelheim Pharma Kg | Process for preparing powder formulations |
AP1712A (en) * | 2000-10-12 | 2007-01-24 | Boehringer Ingelheim Pharma | Novel tiotropium-containing inhalation powder |
CZ301465B6 (en) * | 2000-10-12 | 2010-03-10 | Boehringer Ingelheim Pharma Gmbh & Co. Kg. | Inhalation powder containing tiotropium |
US6585959B2 (en) | 2000-10-12 | 2003-07-01 | Boehringer Ingelheim Pharma Kg | Process for preparing powder formulations |
EP1430887A1 (en) * | 2000-10-12 | 2004-06-23 | Boehringer Ingelheim Pharma GmbH & Co.KG | Powder for inhalation containing Tiotropium |
US7070800B2 (en) | 2000-10-12 | 2006-07-04 | Boehringer Ingelheim Pharma Kg | Inhalable powder containing tiotropium |
WO2002030389A1 (en) * | 2000-10-12 | 2002-04-18 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Novel tiotropium-containing inhalation powder |
US6890517B2 (en) | 2000-10-31 | 2005-05-10 | Boehringer Ingelheim Pharma Kg | Inhalable formulation of a solution containing a tiotropium salt |
EP1690539A2 (en) * | 2001-03-13 | 2006-08-16 | Boehringer Ingelheim Pharma GmbH & Co. KG | Salts of tiotropium for treating inflammatory disorders |
US7994188B2 (en) | 2001-03-13 | 2011-08-09 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Compounds for treating inflammatory diseases |
WO2002072095A2 (en) * | 2001-03-13 | 2002-09-19 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Tiotropium salts for treating inflammatory diseases |
WO2002072095A3 (en) * | 2001-03-13 | 2003-11-27 | Boehringer Ingelheim Pharma | Tiotropium salts for treating inflammatory diseases |
EP1690539A3 (en) * | 2001-03-13 | 2006-08-30 | Boehringer Ingelheim Pharma GmbH & Co. KG | Salts of tiotropium for treating inflammatory disorders |
JP2004528305A (en) * | 2001-03-13 | 2004-09-16 | ベーリンガー インゲルハイム ファルマ ゲゼルシャフト ミット ベシュレンクテル ハフツング ウント コンパニー コマンディトゲゼルシャフト | Compounds for treating inflammatory diseases |
US6667344B2 (en) | 2001-04-17 | 2003-12-23 | Dey, L.P. | Bronchodilating compositions and methods |
US9597396B2 (en) | 2001-04-17 | 2017-03-21 | Mylan Specialty Lp | Formoterol/steroid bronchodilating compositions and methods of use thereof |
WO2002100319A3 (en) * | 2001-06-13 | 2003-03-20 | Boehringer Ingelheim Pharma | Method for cleaning hard gelatine capsules |
WO2002100319A2 (en) * | 2001-06-13 | 2002-12-19 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Method for cleaning hard gelatine capsules |
EP1785422B1 (en) * | 2002-03-20 | 2016-11-16 | Boehringer Ingelheim Pharma GmbH & Co. KG | Micronised crystalline tiotropium bromide |
NO346754B1 (en) * | 2002-03-20 | 2022-12-12 | Boehringer Ingelheim Pharma | Crystalline micronisate of tiotropium bromide |
NO344427B1 (en) * | 2002-03-20 | 2019-12-02 | Boehringer Ingelheim Pharma | Process for the preparation of crystalline tiotropium bromide micronisate |
EP3053921A1 (en) * | 2002-03-20 | 2016-08-10 | Boehringer Ingelheim Pharma GmbH & Co. KG | Crystalline micronisate of tiotropium bromide |
US8022082B2 (en) | 2002-04-09 | 2011-09-20 | Boehringer Ingelheim Pharma Gmbh & Co., Kg | Method for the administration of an anticholinergic by inhalation |
EP2319585A1 (en) | 2002-08-29 | 2011-05-11 | Cipla Ltd. | Pharmaceutical products and compositions comprising salmeterol, fluticasone and ipratropium or tiotropium |
EP2329861A1 (en) | 2002-08-29 | 2011-06-08 | Cipla Ltd. | Pharmaceutical products and compositions comprising formoterol, budesonide and ipratropium |
EP2319582A1 (en) | 2002-08-29 | 2011-05-11 | Cipla Ltd. | Pharmaceutical products and compositions comprising formoterol, budesonide and tiotropium or oxitropium |
EP2319583A1 (en) | 2002-08-29 | 2011-05-11 | Cipla Ltd. | Pharmaceutical products and compositions comprising salmeterol, budesonide and ipratropium |
EP2322243A1 (en) | 2002-08-29 | 2011-05-18 | Cipla Ltd. | Pharmaceutical products and compositions comprising formoterol, ciclesonide and tiotropium |
EP2319584A1 (en) | 2002-08-29 | 2011-05-11 | Cipla Ltd. | Pharmaceutical products and compositions comprising salmeterol, ciclesonide and tiotropium |
WO2004024156A1 (en) * | 2002-09-13 | 2004-03-25 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Tiotropium salts for reducing respiratory mortality rate |
EA011549B1 (en) * | 2002-11-28 | 2009-04-28 | Бёрингер Ингельхайм Фарма Гмбх Унд Ко. Кг | Novel pulverulent formulation for inhalation containing tiotropium |
US7763280B2 (en) | 2002-11-28 | 2010-07-27 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Tiotropium containing powder formulation for inhalation |
US8197845B2 (en) | 2002-11-28 | 2012-06-12 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Encapsulated tiotropium containing powder formulation for inhalation |
WO2004047796A2 (en) * | 2002-11-28 | 2004-06-10 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Pulverulent formulation for inhalation containing tiotropium |
WO2004047796A3 (en) * | 2002-11-28 | 2004-09-30 | Boehringer Ingelheim Pharma | Pulverulent formulation for inhalation containing tiotropium |
EP2228064B1 (en) | 2004-05-18 | 2019-12-11 | Novartis AG | Pharmaceutical composition containing glycopyrrolate and a beta2 adrenoceptor agonist |
US8044205B2 (en) | 2006-07-21 | 2011-10-25 | Laboratorios Almirall, S.A. | Process for manufacturing 3(R)-(2-hydroxy-2,2-dithien-2-ylacetoxy)-1-(3-phenoxypropyl)-1-azoniabicyclo[2.2.2]octane bromide |
WO2009090010A1 (en) * | 2008-01-15 | 2009-07-23 | Chiesi Farmaceutici S.P.A. | Compositions comprising an antimuscarinic and a long-acting beta-agonist |
EP2080523A1 (en) * | 2008-01-15 | 2009-07-22 | CHIESI FARMACEUTICI S.p.A. | Compositions comprising an antimuscarinic and a long-acting beta-agonist |
US10085974B2 (en) | 2008-03-13 | 2018-10-02 | Almirall, S.A. | Dosage and formulation |
US9254262B2 (en) | 2008-03-13 | 2016-02-09 | Almirall, S.A. | Dosage and formulation |
US11000517B2 (en) | 2008-03-13 | 2021-05-11 | Almirall, S.A. | Dosage and formulation |
WO2011037551A3 (en) * | 2009-09-23 | 2011-06-09 | Mahmut Bilgic | Carrying of a combination containing tiotropium in a blister strip |
WO2011037549A3 (en) * | 2009-09-23 | 2011-06-09 | Bilgic Mahmut | Dry powder formulation of tiotropium carried in blister strip |
WO2011049538A3 (en) * | 2009-10-20 | 2011-11-03 | Bilgic Mahmut | Pharmaceutical composition in dry powder form |
WO2011078816A1 (en) | 2009-12-25 | 2011-06-30 | Bilgic Mahmut | Dry powder combination of tiotropium, formoterol and a cromoglicic acid derivative |
US8834931B2 (en) | 2009-12-25 | 2014-09-16 | Mahmut Bilgic | Dry powder formulation containing tiotropium for inhalation |
US9737520B2 (en) | 2011-04-15 | 2017-08-22 | Almirall, S.A. | Aclidinium for use in improving the quality of sleep in respiratory patients |
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CA2360248C (en) | Combinations of formoterol and a tiotropium salt | |
CA2362499C (en) | Combinations of formoterol and mometasone furoate for asthma | |
EP1152753B1 (en) | Combinations of formoterol and fluticasone propionate for asthma | |
MXPA01008001A (en) | Combinations of formoterol and a tiotropium salt | |
MXPA01008879A (en) | Combinations of formoterol and mometasone furoate for asthma | |
MXPA01008360A (en) | Combinations of formoterol and fluticasone propionate for asthma |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
WWE | Wipo information: entry into national phase |
Ref document number: 1200100643 Country of ref document: VN Ref document number: 00803395.1 Country of ref document: CN |
|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE DK DM EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): GH GM KE LS MW SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
WWE | Wipo information: entry into national phase |
Ref document number: 2000902663 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 143986 Country of ref document: IL |
|
WWE | Wipo information: entry into national phase |
Ref document number: 24419/00 Country of ref document: AU |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2001/05648 Country of ref document: ZA Ref document number: 200105648 Country of ref document: ZA |
|
WWE | Wipo information: entry into national phase |
Ref document number: IN/PCT/2001/1052/CHE Country of ref document: IN |
|
WWE | Wipo information: entry into national phase |
Ref document number: 513304 Country of ref document: NZ |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2001/02226 Country of ref document: TR |
|
WWE | Wipo information: entry into national phase |
Ref document number: 11272001 Country of ref document: SK Ref document number: PV2001-2856 Country of ref document: CZ |
|
ENP | Entry into the national phase |
Ref document number: 2360248 Country of ref document: CA Ref document number: 2360248 Country of ref document: CA Kind code of ref document: A Ref document number: 2000 598152 Country of ref document: JP Kind code of ref document: A |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1020017009941 Country of ref document: KR |
|
WWE | Wipo information: entry into national phase |
Ref document number: 09924246 Country of ref document: US Ref document number: PA/a/2001/008001 Country of ref document: MX |
|
WWP | Wipo information: published in national office |
Ref document number: 1020017009941 Country of ref document: KR Ref document number: PV2001-2856 Country of ref document: CZ |
|
WWP | Wipo information: published in national office |
Ref document number: 2000902663 Country of ref document: EP |
|
REG | Reference to national code |
Ref country code: DE Ref legal event code: 8642 |
|
WWG | Wipo information: grant in national office |
Ref document number: 24419/00 Country of ref document: AU |
|
WWR | Wipo information: refused in national office |
Ref document number: 1020017009941 Country of ref document: KR |
|
WWG | Wipo information: grant in national office |
Ref document number: 2000902663 Country of ref document: EP |